Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingwei Zhitong (QZ) is a Traditional Chinese Medicine (TCM) formulation, typically prepared as pellets (micropills), used for the treatment of gastric conditions including *Helicobacter pylori* infection and associated stomach pain. In clinical research, it has been evaluated as a component of a 14-day quadruple therapy (QZQT), where it serves as an alternative to bismuth. Studies indicate that QZ-containing therapy achieves eradication rates comparable to standard bismuth-containing quadruple therapy (BQT) but with a significantly lower incidence of side effects and improved patient compliance. The formulation is traditionally indicated to clear stomach heat and provide analgesic effects in the gastrointestinal tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingwei zhitong.